Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;19(5):102512.
doi: 10.1016/j.autrev.2020.102512. Epub 2020 Mar 12.

Clinical outcome measures in multiple sclerosis: A review

Affiliations
Review

Clinical outcome measures in multiple sclerosis: A review

Hernan Inojosa et al. Autoimmun Rev. 2020 May.

Abstract

A proper clinical evaluation of patients with Multiple Sclerosis (MS) is of great importance to detect MS progression. It provides important data for physicians on their daily practice as well as with scientific purpose, especially useful with the development of newer therapeutic options in MS. Clinical outcome measures (COMs) are instruments that enable a standardized characterization of the patient's clinical disease status. A proper COM should have - among other psychometric characteristics - a good validity, reliability and responsiveness. For MS disability, the Expanded Disability Status Scale (EDSS) is currently the most frequently used scale. However, different less known COMs are also available and could be implemented on clinical practice. We review the most frequently used COMs of MS progression including their operationalization and statistical considerations, as well as newer composite COMs and digital tools on development. We focus on their responsiveness or capacity to detect clinically relevant changes to identify progression or transition to progressive forms of the disease, as well as therapeutic response.

Keywords: Assessment tools; Clinical Outcome Measures (COM); Expanded Disability Status Scale (EDSS); Multiple Sclerosis Functional Composite (MSFC); Multiple Sclerosis Performance Test (MSPT); Multiple sclerosis; Patient Determined Disease Step (PDDS).

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest HI and DS declare that they have no conflict of interest. TZ received personal compensation from Biogen, Bayer, Celgene, Novartis, Roche, Sanofi, Teva for the consulting services. Ziemssen received additional financial support for the research activities from Bayer, Biogen, Novartis, Teva, and Sanofi.

LinkOut - more resources